Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Jing-Zhou Hou, Tae Min Kim, Seok-Goo Cho, Sameh Gaballa, Ranjit Nair, Koji Izutsu, Sumana Devata, Dok Hyun Yoon, Won-Seog Kim, Yazeed Sawalha, Ryan Jacobs, Eliza Hawkes, Ming-Chung Wang, Constantine Tam, Don Stevens, Hisayuki Yokoyama, Jin Seok Kim, Matthew Matasar, Aravind Ramakrishnan, Denise Brennan, David Sermer, Robin Lesley, Mihail Obrocea, Dai Maruyama
Institutions: UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Seoul National University Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, National Cancer Centre Japan, Medical College of Wisconsin, Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Levine Cancer Institute, Austin Health, Kaohsiung Chang Gung Memorial Hospital, The Alfred Hospital, Monash University, Norton Healthcare, Yamagata University, Yonsei University, Severance Hospital, Rutgers Cancer Institute, St David's Medical Center, AstraZeneca (United States), Japanese Foundation For Cancer Research
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015669